<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059202</url>
  </required_header>
  <id_info>
    <org_study_id>URSO (completed)</org_study_id>
    <secondary_id>R01DK056924</secondary_id>
    <nct_id>NCT00059202</nct_id>
  </id_info>
  <brief_title>Trial of High-dose Urso in Primary Sclerosing Cholangitis</brief_title>
  <official_title>Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for&#xD;
      patients with primary sclerosing cholangitis (PSC). The average duration of follow-up will be&#xD;
      approximately five years with important clinical endpoints such as death, eligibility for&#xD;
      liver transplantation, changes in histology and cholangiogram as well as liver biochemistries&#xD;
      and quality of life data collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB reviewed interim analysis and terminated the study due to futility.&#xD;
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Failure</measure>
    <time_frame>5 years</time_frame>
    <description>Treatment failure was defined as death, transplantation, meeting minimal listing criteria, development of varices, cholangiocarcinoma, or progression to cirrhosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>5 years</time_frame>
    <description>Death at any time up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have a Liver Transplantation</measure>
    <time_frame>5 years</time_frame>
    <description>Liver transplantation at any time up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Meeting Minimal Listing Criteria for Liver Transplantation</measure>
    <time_frame>5 years</time_frame>
    <description>Meeting minimal listing criteria for liver transplantation at any time up to 5 years. Minimal listing criteria are defined as a MELD score of 14 or higher. The Model For End-Stage Liver Disease (MELD) is a numeric score with a range of 6 to 40, where a higher score means worse liver disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Cholangiocarcinoma</measure>
    <time_frame>5 years</time_frame>
    <description>Development of cholangiocarcinoma at any time up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Varices</measure>
    <time_frame>5 years</time_frame>
    <description>Development of esophogeal and/or gastric varices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Cirrhosis</measure>
    <time_frame>5 years</time_frame>
    <description>Development of cirrhosis based on liver biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Alkaline phosphatase divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Alkaline phosphatase divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Alkaline phosphatase divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Bilirubin divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Bilirubin divided by the upper limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin at 36 Months</measure>
    <time_frame>36 months</time_frame>
    <description>Bilirubin divided by the upper limit of normal</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet that is identical (size, color, etc) to experimental ursodeoxycholic acid tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodeoxycholic acid 28-30 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
    <arm_group_label>Ursodeoxycholic acid</arm_group_label>
    <other_name>UDCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Urso</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Chronic cholestatic disease of at least six months' duration.&#xD;
&#xD;
          -  Serum alkaline phosphatase at least 1 Â½ times the upper limits of normal.&#xD;
&#xD;
          -  Retrograde, operative, percutaneous, or magnetic resonance cholangiography&#xD;
             demonstrating intrahepatic and/or extrahepatic biliary duct obstruction, beading, or&#xD;
             narrowing consistent with PSC within one year of the study entry.&#xD;
&#xD;
          -  Liver biopsy in the previous one year which is available for review and compatible&#xD;
             with the diagnosis of PSC. Compatible biopsy features include fibrous cholangitis,&#xD;
             ductopenia with periportal inflammation and biliary fibrosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009 Sep;50(3):808-14. doi: 10.1002/hep.23082.</citation>
    <PMID>19585548</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2003</study_first_submitted>
  <study_first_submitted_qc>April 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2003</study_first_posted>
  <results_first_submitted>March 12, 2021</results_first_submitted>
  <results_first_submitted_qc>March 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urso</keyword>
  <keyword>PSC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ursodeoxycholic Acid</title>
          <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo for Urso</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>drug toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ursodeoxycholic Acid</title>
          <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo for Urso</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" lower_limit="20.5" upper_limit="75.6"/>
                    <measurement group_id="B2" value="45.3" lower_limit="17.9" upper_limit="73.6"/>
                    <measurement group_id="B3" value="46.6" lower_limit="17.9" upper_limit="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Failure</title>
        <description>Treatment failure was defined as death, transplantation, meeting minimal listing criteria, development of varices, cholangiocarcinoma, or progression to cirrhosis</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Failure</title>
          <description>Treatment failure was defined as death, transplantation, meeting minimal listing criteria, development of varices, cholangiocarcinoma, or progression to cirrhosis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths</title>
        <description>Death at any time up to 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo or Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths</title>
          <description>Death at any time up to 5 years</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have a Liver Transplantation</title>
        <description>Liver transplantation at any time up to 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic acid 28-30 mg/kg/day&#xD;
Ursodeoxycholic Acid: Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have a Liver Transplantation</title>
          <description>Liver transplantation at any time up to 5 years</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Meeting Minimal Listing Criteria for Liver Transplantation</title>
        <description>Meeting minimal listing criteria for liver transplantation at any time up to 5 years. Minimal listing criteria are defined as a MELD score of 14 or higher. The Model For End-Stage Liver Disease (MELD) is a numeric score with a range of 6 to 40, where a higher score means worse liver disease.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Meeting Minimal Listing Criteria for Liver Transplantation</title>
          <description>Meeting minimal listing criteria for liver transplantation at any time up to 5 years. Minimal listing criteria are defined as a MELD score of 14 or higher. The Model For End-Stage Liver Disease (MELD) is a numeric score with a range of 6 to 40, where a higher score means worse liver disease.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Cholangiocarcinoma</title>
        <description>Development of cholangiocarcinoma at any time up to 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Cholangiocarcinoma</title>
          <description>Development of cholangiocarcinoma at any time up to 5 years</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Varices</title>
        <description>Development of esophogeal and/or gastric varices</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Varices</title>
          <description>Development of esophogeal and/or gastric varices</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Cirrhosis</title>
        <description>Development of cirrhosis based on liver biopsy</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Cirrhosis</title>
          <description>Development of cirrhosis based on liver biopsy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alkaline Phosphatase at 12 Months</title>
        <description>Alkaline phosphatase divided by the upper limit of normal</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase at 12 Months</title>
          <description>Alkaline phosphatase divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.6" upper_limit="9.1"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.6" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alkaline Phosphatase at 24 Months</title>
        <description>Alkaline phosphatase divided by the upper limit of normal</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase at 24 Months</title>
          <description>Alkaline phosphatase divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.6" upper_limit="8.5"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.5" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alkaline Phosphatase at 36 Months</title>
        <description>Alkaline phosphatase divided by the upper limit of normal</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase at 36 Months</title>
          <description>Alkaline phosphatase divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.6" upper_limit="16.5"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.4" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase at 12 Months</title>
        <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase at 12 Months</title>
          <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.5" upper_limit="10.5"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.6" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase at 24 Months</title>
        <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase at 24 Months</title>
          <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.4" upper_limit="8.4"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.5" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase at 36 Months</title>
        <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase at 36 Months</title>
          <description>Aspartate aminotransferase at divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.3" upper_limit="7.2"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.5" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin at 12 Months</title>
        <description>Bilirubin divided by the upper limit of normal</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin at 12 Months</title>
          <description>Bilirubin divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.2" upper_limit="6.3"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.3" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin at 24 Months</title>
        <description>Bilirubin divided by the upper limit of normal</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin at 24 Months</title>
          <description>Bilirubin divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.2" upper_limit="7.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bilirubin at 36 Months</title>
        <description>Bilirubin divided by the upper limit of normal</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ursodeoxycholic Acid</title>
            <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for Urso</description>
          </group>
        </group_list>
        <measure>
          <title>Bilirubin at 36 Months</title>
          <description>Bilirubin divided by the upper limit of normal</description>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.2" upper_limit="15.9"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.3" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ursodeoxycholic Acid</title>
          <description>Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo for Urso</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Keith Lindor</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-2511</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

